Navigation Links
Diabetes makes it hard for blood vessels to relax
Date:1/31/2008

osed with the recommendation the supplement not be used by heart attack patients. The supplement still is widely marketed.

The findings of increased arginase I activity in diabetes may limit other therapeutic approaches proposed for early endothelial dysfunction such as oral L-arginine supplementation, Drs. Thomas L. Luscher and Jan Steffel, of the University of Zurich Cardiovascular Research Institute write in an accompanying editorial. Although dietary L-arginine supplementation has been shown to exert vascular protective effects in certain clinical settings, this approach is unlikely to be effective in diabetes, if the results of this study can be confirmed by patients in vivo. In fact, the findings of Romera et al may provide a possible explanation for the unexpected neutral or even adverse effects of oral L-arginine in some clinical studies, in particular patients with coronary artery disease and infarction.

A short intravenous course of L-arginine may provide short-term improvement in blood vessel tone, Dr. Romero notes. However most of L-arginine ingested goes directly to the liver to be broken down, not the bloodstream where it can promote relaxation of blood vessels, Dr. Romero says.

Arginase also is associated with vascular problems related to aging, hypertension, sickle cell disease, atherosclerosis and erectile dysfunction, Dr. Romero says. L-citrulline already is taken by some sickle cell patients to reduce breath-taking fibrosis in their lungs. In addition to helping the body turn toxins into urea that can be safely eliminated from the body, arginase also helps in collagen formation and cell proliferation, but too much can be bad. In fact, Drs. Caldwell and Romero are pursuing studies of how increased arginase activity may harden blood vessel walls.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert

Page: 1 2

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Gender, coupled with diabetes, affects vascular disease development
3. Breakthrough research identifies how cells from pigs may cure diabetes
4. Botched production of insulin molecule may lead to diabetes
5. Joslin researchers uncover potential role of leptin in diabetes
6. Insulins brain impact links drugs and diabetes
7. Exercise improves thinking, reduces diabetes risk in overweight children
8. UVa Health System team uncovers genes role in type 1 diabetes
9. Childrens Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
10. JDRF awards University of Copenhagen professor with grant to conduct innovative diabetes research
11. Cancer and arthritis therapy may be promising treatment for diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 4Tropical forests affected by habitat fragmentation store less biomass and carbon dioxide 2Tropical forests affected by habitat fragmentation store less biomass and carbon dioxide 3CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2U S Food And Drug Administration 28FDA 29 Grants Traditional Approval for INTELENCE 28R 29 28etravirine 29 6543 1U S Food And Drug Administration 28FDA 29 Grants Traditional Approval for INTELENCE 28R 29 28etravirine 29 6543 2U S Food And Drug Administration 28FDA 29 Grants Traditional Approval for INTELENCE 28R 29 28etravirine 29 6543 3U S Food And Drug Administration 28FDA 29 Grants Traditional Approval for INTELENCE 28R 29 28etravirine 29 6543 4Hormone ghrelin can boost resistance to Parkinsons disease 10903 1Hormone ghrelin can boost resistance to Parkinsons disease 10903 2Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 1Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 2Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 3Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 4Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 5
Other Biology Technology:Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 2Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 3Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 4Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 5Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 6Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 7Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 8Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 9Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 10Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 11Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 12Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 13Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 14Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 15Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 16Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements 2Genta Incorporated to Present at the BIO CEO & Investor Conference 2Genta Incorporated to Present at the BIO CEO & Investor Conference 3